Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii

References

• Centers for Disease Prevention and Control. Antibiotic Resistance Threats in the United States (2019). https://www.cdc.gov/drugresistance/biggest-threats.html ( Accessed 14 January 2024).
   Google Scholar
• European Centre for Disease Prevention and Control. Rapid Risk Assessment: Carbapenem-resistant Acinetobacter baumannii in Healthcare Settings (2016). https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-carbapenem-resistant-Acinetobacter-baumannii-healthcare ( Accessed 14 January 2024).
   Google Scholar
• Cain AK, Hamidian M. Portrait of a killer: uncovering resistance mechanisms and global spread of Acinetobacter baumannii. PLOS Pathog. 19(8), e1011520 (2023).
   PubMed Web of Science ®Google Scholar
• Lemos EV, de la Hoz FP, Einarson TR et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clin. Microbiol. Infect. 20(5), 416–423 (2014).
   PubMed Web of Science ®Google Scholar
• Falcone M, Tiseo G, Carbonara S et al. Mortality Attributable to Bloodstream Infections Caused by Different Carbapenem-Resistant Gram-Negative Bacilli: Results From a Nationwide Study in Italy (ALARICO Network). Clin. Infect. Dis. 76(12), 2059–2069 (2023).
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Weinstein RA. Acinetobacter infection. N. Engl. J. Med. 358(12), 1271–1281 (2008).
   PubMed Web of Science ®Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Antimicrobial Resistant Treatment Guidance: Gram-Negative Bacterial Infections. Clin. Infect. Dis. ciad428 (2023).
   PubMedGoogle Scholar
• Karakonstantis S, Ioannou P, Samonis G, Kofteridis DP. Systematic review of antimicrobial combination options for pandrug-resistant Acinetobacter baumannii. Antibiotics 10(11), 1344 (2021).
   Google Scholar
• XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use. Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf ( Accessed 14 January 2024).
   Google Scholar
• Adnan S, Paterson DL, Lipman J, Roberts JA. Ampicillin/sulbactam: its potential use in treating infections in critically ill patients. Int. J. Antimicrob. Agents 42(5), 384–389 (2013).
   PubMed Web of Science ®Google Scholar
• Shapiro AB. Kinetics of sulbactam hydrolysis by β-lactamases, and kinetics of β-lactamase inhibition by Sulbactam. Antimicrob. Agents Chemother. 61(12), e01612–01617 (2017).
   PubMed Web of Science ®Google Scholar
• Noguchi JK, Gill MA. Sulbactam: a β-lactamase inhibitor. Clin. Pharm. 7(1), 37–51 (1988).
   PubMedGoogle Scholar
• Penwell WF, Shapiro AB, Giacobbe RA et al. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob. Agents Chemother. 59(3), 1680–1689 (2015).
   PubMed Web of Science ®Google Scholar
• Krizova L, Poirel L, Nordmann P, Nemec A. TEM-1 β-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii. J. Antimicrob. Chemother. 68(12), 2786–2791 (2013).
   PubMed Web of Science ®Google Scholar
• Kuo S-C, Lee Y-T, Yang Lauderdale T-L et al. Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii. Front. Microbiol. 6, 231 (2015).
   PubMed Web of Science ®Google Scholar
• Durand-Réville TF, Guler S, Comita-Prevoir J et al. ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat. Microbiol. 2, 17104 (2017).
   PubMed Web of Science ®Google Scholar
• Castanheira M, Mendes RE, Gales AC. Global epidemiology and mechanisms of resistance of Acinetobacter baumannii-calcoaceticus complex. Clin. Infect. Dis. 76(Suppl. 2), S166–S178 (2023).
   PubMedGoogle Scholar
• Shapiro AB, Gao N, Jahić H, Carter NM, Chen A, Miller AA. Reversibility of covalent, broad-spectrum serine β-lactamase inhibition by the diazabicyclooctenone ETX2514. ACS Infect. Dis. 3(11), 833–844 (2017).
   PubMed Web of Science ®Google Scholar
• Petropoulou D, Siopi M, Vourli S, Pournaras S. Activity of sulbactam–durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece. Front. Cell. Infect. Microbiol. 11, 814530 (2021).
   PubMed Web of Science ®Google Scholar
• Seifert H, Müller C, Stefanik D, Higgins PG, Miller A, Kresken M. In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 75(9), 2616–2621 (2020).
   PubMed Web of Science ®Google Scholar
• Nodari CS, Santos FF, Kurihara MNL, Valiatti TB, Cayô R, Gales AC. In vitro activity of sulbactam/durlobactam against extensively drug-resistant Acinetobacter baumannii isolates belonging to South American major clones. J. Glob. Antimicrob. Resist. 25, 363–366 (2021).
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Hackel MA, McLeod SM, Miller AA. In vitro activity of sulbactam–durlobactam against global isolates of Acinetobacter baumannii - calcoaceticus complex collected from 2016 to 2021. Antimicrob. Agents Chemother. 66(9), e00781–22 (2022).
   PubMed Web of Science ®Google Scholar
• Findlay J, Poirel L, Bouvier M, Nordmann P. In vitro activity of sulbactam–durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance. J. Glob. Antimicrob. Resist. 30, 445–450 (2022).
   PubMed Web of Science ®Google Scholar
• Yang Q, Xu Y, Jia P et al. In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China. J. Antimicrob. Chemother. 75(7), 1833–1839 (2020).
   PubMed Web of Science ®Google Scholar
• FDA. Antimicrobial susceptibility test interpretive criteria. sulbactam–durlobactam. https://www.fda.gov/drugs/development-resources/sulbactam-and-durlobactam-injection ( Accessed 14 January 2024).
   Google Scholar
• McLeod SM, Shapiro AB, Moussa SH et al. Frequency and mechanism of spontaneous resistance to sulbactam combined with the novel β-lactamase inhibitor ETX2514 in clinical isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother. 62(2), e01576–17 (2018).
   PubMed Web of Science ®Google Scholar
• McLeod SM, Moussa SH, Hackel MA, Miller AA. In vitro activity of sulbactam–durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally in 2016 and 2017. Antimicrob. Agents Chemother. 64(4), e02534–19 (2020).
   PubMed Web of Science ®Google Scholar
• Moussa SH, Shapiro AB, McLeod SM et al. Molecular drivers of resistance to sulbactam–durlobactam in contemporary clinical isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother. 67(11), e0066523 (2023).
   PubMedGoogle Scholar
• Barnes MD, Kumar V, Bethel CR et al. Targeting multidrug-resistant Acinetobacter spp.: sulbactam and the diazabicyclooctenone β-lactamase inhibitor ETX2514 as a novel therapeutic agent. mBio 10(2), e00159–19 (2019).
   PubMed Web of Science ®Google Scholar
• Mussi MA, Limansky AS, Viale AM. Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii: natural insertional inactivation of a gene encoding a member of a novel family of β-barrel outer membrane proteins. Antimicrob. Agents Chemother. 49(4), 1432–1440 (2005).
   PubMed Web of Science ®Google Scholar
• Iyer R, Moussa SH, Durand-Réville TF, Tommasi R, Miller A. Acinetobacter baumannii OmpA Is a selective antibiotic permeant porin. ACS Infect. Dis. 4(3), 373–381 (2018).
   PubMed Web of Science ®Google Scholar
• Corbella X, Ariza J, Ardanuy C et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J. Antimicrob. Chemother. 42(6), 793–802 (1998).
   PubMed Web of Science ®Google Scholar
• Obana Y, Nishino T. In-vitro and in-vivo activities of sulbactam and YTR830H against Acinetobacter calcoaceticus. J. Antimicrob. Chemother. 26(5), 677–682 (1990).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Hernández MJ, Cuberos L, Pichardo C et al. Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. J. Antimicrob. Chemother. 47(4), 479–482 (2001).
   PubMed Web of Science ®Google Scholar
• Wolff M, Joly-Guillou ML, Farinotti R, Carbon C. In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob. Agents Chemother. 43(6), 1406–1411 (1999).
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Matsumoto K, Ikawa K et al. Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models. Int. J. Antimicrob. Agents 43(6), 547–552 (2014).
   PubMed Web of Science ®Google Scholar
• Housman ST, Hagihara M, Nicolau DP, Kuti JL. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 68(10), 2296–2304 (2013).
   PubMed Web of Science ®Google Scholar
• Bulitta JB, Hope WW, Eakin AE et al. Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans. Antimicrob. Agents Chemother. 63(5), e02307–02318 (2019).
   PubMed Web of Science ®Google Scholar
• O'Donnell JP, Bhavnani SM. The pharmacokinetics/pharmacodynamic relationship of durlobactam in combination with sulbactam in in vitro and in vivo infection model systems versus Acinetobacter baumannii-calcoaceticus complex. Clin. Infect. Dis. 76(Suppl. 2), S202–S209 (2023).
   PubMedGoogle Scholar
• U.S. Food and Drug Administration. Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antibacterial-therapies-patients-unmet-medical-need-treatment-serious-bacterial-diseases
   Google Scholar
• Lickliter JD, Lawrence K, O'Donnell J, Isaacs R. Safety, pharmacokinetics, and drug-drug interaction potential of intravenous durlobactam, a β-lactamase inhibitor, in healthy subjects. Antimicrob. Agents Chemother. 64(7), e00071–20 (2020).
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Gotfried MH, Isaacs RD, O'Donnell JP, Stone E. Plasma and intrapulmonary concentrations of ETX2514 and sulbactam following intravenous administration of ETX2514SUL to healthy adult subjects. Antimicrob. Agents Chemother. 62(11), e01089–18 (2018).
   PubMed Web of Science ®Google Scholar
• O'Donnell J, Maloney K, Steidler M, Morrison R, Isaacs R. A randomized, double-blind, placebo- and positive-controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects. Clin. Transl. Sci. 14(4), 1423–1430 (2021).
   PubMed Web of Science ®Google Scholar
• O'Donnell J, Preston RA, Mamikonyan G, Stone E, Isaacs R. Pharmacokinetics, safety, and tolerability of intravenous durlobactam and sulbactam in subjects with renal impairment and healthy matched control subjects. Antimicrob. Agents Chemother. 63(9), e00794–19 (2019).
   PubMed Web of Science ®Google Scholar
• Sagan O, Yakubsevitch R, Yanev K et al. Pharmacokinetics and tolerability of intravenous sulbactam–durlobactam with imipenem-cilastatin in hospitalized adults with complicated urinary tract infections, including acute pyelonephritis. Antimicrob. Agents Chemother. 64(3), e01506–01519 (2020).
   PubMed Web of Science ®Google Scholar
• Kaye KS, Shorr AF, Wunderink RG et al. Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect. Dis. 23(9), 1072–1084 (2023).
   PubMed Web of Science ®Google Scholar
• Hartzell JD, Neff R, Ake J et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin. Infect. Dis. 48(12), 1724–1728 (2009).
   PubMed Web of Science ®Google Scholar
• Bartal C, Rolston KVI, Nesher L. Carbapenem-resistant Acinetobacter baumannii: colonization, infection and current treatment options. Infect. Dis. Ther. 11(2), 683–694 (2022).
   PubMed Web of Science ®Google Scholar
• Bassetti M, Echols R, Matsunaga Y et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase III trial. Lancet Infect. Dis. 21(2), 226–240 (2021).
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Matsunaga Y, Ariyasu M et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase III, non-inferiority trial. Lancet Infect. Dis. 21(2), 213–225 (2021).
   PubMed Web of Science ®Google Scholar
• Choby JE, Ozturk T, Satola SW, Jacob JT, Weiss DS. Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens. Lancet Infect. Dis. 21(5), 597–598 (2021).
   PubMed Web of Science ®Google Scholar
• Marcella S, Kobic E, Carr AL, Georgiades B, Margiotta C. Outcomes using cefiderocol for the treatment of Acinetobacter baumannii infections from the PROVE (real-world evidence) study. Open Forum Infect. Dis. 9, S361–S362 (2022).
   Google Scholar
• Simner PJ, Palavecino EL, Satlin MJ et al. Potential of inaccurate cefiderocol susceptibility results: a CLSI AST subcommittee advisory. J. Clin. Microbiol. 61(4), e0160022 (2023).
   PubMed Web of Science ®Google Scholar
• XERAVA® (eravacycline) for injection, for intravenous use. Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf
   Google Scholar
• Livermore DM, Mushtaq S, Warner M, Woodford N. In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob. Agents Chemother. 60(6), 3840–3844 (2016).
   PubMed Web of Science ®Google Scholar
• Hawser S, Kothari N, Monti F, Morrissey I, Siegert S, Hodges T. In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020. J. Glob. Antimicrob. Resist. 33, 304–320 (2023).
   PubMed Web of Science ®Google Scholar
• Solomkin J, Evans D, Slepavicius A et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating Gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg. 152(3), 224–232 (2017).
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Gardovskis J, Lawrence K et al. IGNITE4: results of a phase III, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections. Clin. Infect. Dis. 69(6), 921–929 (2019).
   PubMed Web of Science ®Google Scholar
• Alosaimy S, Morrisette T, Lagnf AM et al. Clinical outcomes of eravacycline in patients treated predominately for carbapenem-resistant Acinetobacter baumannii. Microbiol. Spectr. 10(5), e0047922 (2022).
   PubMed Web of Science ®Google Scholar
• Scott CJ, Zhu E, Jayakumar RA, Shan G, Viswesh V. Efficacy of eravacycline versus best previously available therapy for adults with pneumonia due to difficult-to-treat resistant (DTR) Acinetobacter baumannii. Ann. Pharmacother. 56(12), 1299–1307 (2022).
   PubMed Web of Science ®Google Scholar
• Iregui A, Landman D, Quale J. Activity of omadacycline and other tetracyclines against contemporary gram-negative pathogens from New York City hospitals. Microb. Drug Resist. Larchmt. N 27(2), 190–195 (2021).
   PubMed Web of Science ®Google Scholar
• Morrisette T, Alosaimy S, Lagnf AM et al. Real-world, multicenter case series of patients treated with oral omadacycline for resistant Gram-negative pathogens. Infect. Dis. Ther. 11(4), 1715–1723 (2022).
   PubMed Web of Science ®Google Scholar
• CLSI. Performance standards for antimicrobial susceptibility testing, M100-S33(33rd ed.). CLSI, PA, USA (2023).
   Google Scholar
• Lenhard JR, Smith NM, Bulman ZP et al. High-dose ampicillin-sulbactam combinations combat polymyxin-resistant Acinetobacter baumannii in a hollow-fiber infection model. Antimicrob. Agents Chemother. 61(3), e01268–16 (2017).
   PubMed Web of Science ®Google Scholar
• Kengkla K, Kongpakwattana K, Saokaew S, Apisarnthanarak A, Chaiyakunapruk N. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J. Antimicrob. Chemother. 73(1), 22–32 (2018).
   PubMed Web of Science ®Google Scholar
• McLeod S, Carter N, Miller A. In vitro susceptibility of Acinetobacter baumannii-calcoaceticus complex (ABC) to sulbactam–durlobactam in combination with a carbapenem. Presented at: ECCMID. Copenhagen, Denmark, P2126, 15–18 April 2023.
   Google Scholar
• Kalil AC, Metersky ML, Klompas M et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin. Infect. Dis. 63(5), e61–e111 (2016).
   PubMed Web of Science ®Google Scholar
• VABOMERE® (meropenem and vaborbactam) for injection, for intravenous use. Prescribing information.
   Google Scholar
• Magiorakos A-P, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18(3), 268–281 (2012).
   PubMed Web of Science ®Google Scholar